Four writers. One standard.
NAD Picks is written by a small desk of specialists. Each writer owns a defined beat — the evidence base, access and cost — and writes under a consistent pen name, a long-standing practice in science and medical journalism.
What earns trust here is the work, not a résumé. Every figure, dose, and claim is traced to its primary source — the trial, the FDA label, the paper of record — and verified before it is published, so you can check any of it for yourself. Bylines are stable: the same name always means the same writer, and the same standard.
Julian Roth
Research & dataTrials, effect sizes, and the primary literature.
View profile →Nadia Feldman
Access & costCost, coverage, access pathways, and side-effect timelines.
View profile →Priya Anand
Pharmacology & mechanismsReceptors, half-lives, drug interactions, and where mechanism outruns evidence.
View profile →Theo Lindqvist
Peptides & longevityPeptides, NAD+, senolytics, and healthspan — graded by human evidence.
View profile →How we research and where we draw the line is set out in our methodology and editorial policy.